A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Investigational New Drugs

Volumn 29, Issue 3, 2011, Pages 489-498

  Hersh, Evan M ^a   O'Day, Steven J ^b   Powderly, John ^c   Khan, Khuda D ^d,i   Pavlick, Anna C ^e   Cranmer, Lee D ^a   Samlowski, Wolfram E ^f   Nichol, Geoffrey M ^g   Yellin, Michael J ^g   Weber, Jeffrey S ^h  

^a UNIVERSITY OF ARIZONA   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c Carolina Bio Oncology Institute   (United States)

^d St Francis Hospital & Health Centers   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f NEVADA CANCER INSTITUTE   (United States)

^g MEDAREX INC   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Elizabethtown Hematology and Oncology   (United States)

Author keywords

CTLA 4; Dacarbazine; Immune therapy; Ipilimumab; Metastatic melanoma

Indexed keywords

DACARBAZINE; IPILIMUMAB;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALLERGIC VASCULITIS; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; COLITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIAPHORESIS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATOCHEZIA; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; INFECTION COMPLICATION; LUNG EMBOLISM; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; SEPSIS; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SURVIVAL RATE; TACHYCARDIA; VITILIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DEMOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE SUBSETS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 79955581263     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9376-8     Document Type: Article

References (32)

1. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150:179-185 (Pubitemid 38352453)
2. Cancer Facts & Figures (2009) American cancer society, Atlanta, GA, USA. http://www.cancer.org/downloads/STT/2009CAFFfinalsecured.pdf Accessed August 31st, 2009
3. Korn EL, Liu PY, Lee SJ et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534 (Pubitemid 351264344)
4. Bedikian AY, Millward M, Pehamberger H et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J Clin Oncol 24:4738-4745 (Pubitemid 46630937)
5. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587-595
6. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2007) Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 33:484-496 (Pubitemid 47333669)
7. Peggs KS, Segal NH, Allison JP (2007) Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12:192-199 (Pubitemid 47333423)
8. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:95-106 (Pubitemid 46160986)
9. Morse MA (2005) Technology evaluation: Ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther 7:588-597
10. Cranmer LD, Hersh E (2007) The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 25:613-631 (Pubitemid 350135746)
11. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283
12. Ridolfi L, Ridolfi R (2009) Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010). Expert Rev Dermatol 4:199-210
13. Hodi FS, Mihm MC, Soiffer RJ et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717 (Pubitemid 36457795)
14. Langer LF, Clay TM, Morse MA (2007) Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 7:1245-1256 (Pubitemid 47305249)
15. Margolin K (2008) Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma. Comm Oncol 5:367-374
16. O'Day SJ, Ibrahim R, DePril Vet al (2008) Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol 26(19s):abstract 9021
17. Weber JS, O'Day S, Urba W et al (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950-5956
18. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377 (Pubitemid 36842552)
19. Attia P, Phan GQ, Maker AVet al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053
20. Maker AV, Phan GQ, Attia P et al (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005-1016 (Pubitemid 41660676)
21. Wolchok JD, Neyns B, Linette G et al (2009) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol; in press
22. Urba WJ, Weber JS, O'Day SJ et al (2008) Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10mg/kg every 3weeks for 4 doses (induction dosing). J Clin Oncol 26(19s):abstract 3018
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
24. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5:397-405
25. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M (2008) Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 9:307-311
26. Ribas A, Camacho LH, Lopez Berestein G et al (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23:8968-8977 (Pubitemid 46217464)
27. Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420
28. Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823-830
29. Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R (2008) An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 26(19s):abstract 9063
30. Weber J (2007) Review: Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864-872
31. Weber J, Thompson JA, Hamid O et al (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598
32. ClinicalTrials.gov. Dacarbazine and ipilimumab vs. dacarbazine with placebo in untreated, unresectable stage III or IV melanoma. www.clinicaltrials.gov/ct/show/NCT00324155 Accessed September 3rd, 2009